New stock news | Real Biotechnology announces listing on the Hong Kong Stock Exchange for the fourth time

According to the app of Wisdom Finance, it is learned that on May 29th, the Hong Kong Stock Exchange disclosed that True BioTech Co., Ltd. (referred to as True BioTech) has submitted its listing application to the main board of the Hong Kong Stock Exchange, with CICC being its exclusive sponsor. This is the company's fourth attempt to apply for listing on the Hong Kong Stock Exchange, having previously submitted applications on August 4, 2022, February 18, 2025, and November 9, 2025. The prospectus shows that True BioTech is a biotechnology company founded in 2012 with innovation and research and development as its driving force, focusing on the development, manufacturing, and commercialization of innovative drugs for the treatment of viral infections, tumors, and cardiovascular and cerebrovascular diseases. The company has built a comprehensive drug portfolio, mainly including seven candidate drugs (including three core products). The company has established a comprehensive research and development platform, including a high-selectivity novel nucleoside broad-spectrum anti-tumor drug research platform, a TOPO1 inhibitor and XDC drug research platform, a drug target discovery and validation platform, and an innovative drug design and optimization platform.